SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings is trending due to a combination of factors, including recent earnings and a low float, leading to speculation about a potential short squeeze. The community is actively discussing price levels, profit-taking strategies, and the stock's potential for significant upward movement. Some traders are wary of the stock's history and caution against chasing gains.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to a recently announced $5 million production order and a $150 million registered direct offering, signaling strong institutional investor confidence. The community is actively discussing the implications of these developments for POET's growth in the AI infrastructure market and its potential to scale production. Discussions include comparing POET to other companies and analyzing the significance of partnerships with major industry players in photonics.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is trending as investors discuss the potential acquisition of Larvotto Resources and the implications of a rejected initial offer, alongside the company's existing DLA contract. Community members are debating the deal's valuation and potential government involvement, while emphasizing UAMY's position as a key domestic antimony producer amid global supply chain concerns and China's export policies. There is also growing anticipation for upcoming earnings announcements and speculation about new deals with Australia and NATO.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as the community reminisces about the stock's past volatility and discusses potential short squeezes, drawing comparisons to other meme stocks like $BYND. A recent White House post using GameStop's slogan has further fueled the conversation and speculative interest. Traders are actively debating potential price movements and the influence of market makers.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending following news of a potential acquisition by Novartis, with the deal speculated to strengthen Novartis's neuroscience pipeline. The community is buzzing about the potential buyout price, the value of the spin-off company, and the implications for the broader RNA therapeutics sector. Some traders point to options activity as a signal and congratulate long-term holders.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending as investors discuss its potential acquisition by INCY and compare it to competitor KURA, particularly focusing on the safety profiles of their respective leukemia treatments. Community members are weighing the impact of a recent FDA approval for Syndax's Revuforj against concerns over a "black box" warning, while also evaluating future revenue potential and possible buyout scenarios.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending after successful flight testing of its Black Widow drone using Palantir's visual navigation software in GPS-denied conditions, marking a potential breakthrough for military applications. The community is actively discussing the implications of this advancement and possible contract opportunities. Some investors express excitement and long-term bullish sentiment, while others are wary of short-term volatility and are actively trading the stock.

Banco BBVA Argentina SA engages in the provision of banking and financial services. It operates through the following business lines: retail banking; small and medium-sized companies; and corporate and investment banking (CIB). The retail banking business includes checking and savings accounts, time deposits, credit cards, personal and auto loans, mortgages, insurance, and investment products. The small and medium-sized companies business focuses on local private-sector companies. The CIB business covers global transaction services and global markets solutions such as risk management and securities brokerage, long term financing products as well as project finance and syndicated loans, and corporate finance services. The company was founded on October 14, 1886 and is headquartered in Buenos Aires, Argentina.

BBVA Argentina - ADR

Banco Bbva Argentina SA

BBAR is trending as investors monitor Argentinian equities following recent political developments, with some anticipating a potential rally due to a shift in leadership. Community members are actively discussing the stock's potential for significant gains, while acknowledging the inherent volatility and risks associated with the Argentinian market. The stock's low P/E ratio and the potential for increased foreign investment are also key discussion points.

YPF SA engages in the exploration, production, and distribution of oil and gas. It operates through the following segments: Upstream, Gas and Power, Downstream, Central Administration and Other. The Upstream segment sells petroleum and natural gas. The Gas and Power segment markets natural gas to third parties and downstream segment; and manages commercial and technical LNG Regasification Terminals in Bahia Blanca and Escobar. The Downstream segment produces petroleum refining and petrochemicals. The Central Administration and Other segment covers corporate administrative expenses and assets, construction activities, and the environmental remediation. The company was founded on June 2, 1977 and is headquartered in Buenos Aires, Argentina.

YPF - ADR

YPF S.A.

YPF is trending due to a rally in Argentina-focused equities, sparked by Javier Milei's election victory; the community is discussing the potential impacts of his policies, including privatization and dollarization, on YPF and the broader Argentine market, while also considering technical factors and unusual options activity.

Global X Funds - Global X MSCI Argentina ETF

The Argentina ETF, ARGT, is trending due to optimism surrounding Argentina's economic direction, particularly following recent political developments and government actions. Community discussions revolve around the potential impact of these changes and the fund's future performance, with some noting the country's ongoing economic challenges. Investors are closely watching how new policies will affect the fund's holdings and the broader Argentinian market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aptevo Therapeutics (APVO) announced on Tuesday that a 100% remission rate was observed in a cohort of its Phase 1b/2 trial evaluating Mipletamig, in combination with Venetoclax and Azacitidine for newly diagnosed patients with acute myeloid leukemia (AML).The <a target="_blank" rel="noopener noreferrer nofollow" href="https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/mipletamig-delivers-100-remission-rate-cohort-3-rainier-trial">study</a> enrolled patients unfit for intensive chemotherapy. No dose-limiting toxicities or cytokine release syndrome were observed in the trial or among any frontline patients treated with Mipletamig to date, the company said.The 100% remission rate achieved at the highest dose level of the trial demonstrated the drug’s potential to redefine the frontline treatment landscape for newly diagnosed AML patients who are unfit for intensive chemotherapy, the company said. It added that 40% of treated patients achieved minimal residual disease (MRD)-negative status, a critical marker of remission.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/APVO">APVO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels. Shares of the company traded 8% higher at the time of writing.<figure class="image"><img style="aspect-ratio:573/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_2_26_05_PM_png_6c3f4781c1.webp" alt="APVO's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Sept. 16, 2025 | Source: Stocktwits" width="573" height="61"><figcaption>APVO's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Sept. 16, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed concerns about a potential dip in the share price.<stembedurl>https://stocktwits.com/WEL16/message/628866258</stembedurl>Another highlighted the drop in share price after the initial jump following the news.&nbsp;<stembedurl>https://stocktwits.com/Avior68/message/628866230</stembedurl>The company said that it is actively enrolling patients for the next cohort at the next dose levels and will present current findings at a medical conference in the last quarter.APVO stock is down by 98% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-fda-alleges-novo-nordisk-video-on-weight-loss-drugs-featuring-oprah-winfrey-is-false-or-misleading/chwyFEyRdzF">US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Aptevo Therapeutics Stock Rallies On 100% Remission Rate In Acute Myeloid Leukemia Trial Cohort

The company stated that the 100% remission rate achieved at the highest dose level of the trial demonstrated the drug’s potential to redefine the frontline treatment landscape for newly diagnosed AML patients who are unfit for intensive chemotherapy.

Equity

Shares of Aptevo Therapeutics Inc. (APVO) rocketed 41% on Thursday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/aptevo-therapeutics-21-million-registered-direct-offering-and">said</a> it is looking to raise about $2.1 million in a registered direct offering and warrants sale.The company said it has entered into definitive securities purchase agreements for the purchase and sale of 1.76 million shares of its common stock in a registered direct offering and warrants to purchase up to 3.5 million shares of common stock in a concurrent private placement at a combined purchase price of $1.19 per share and accompanying warrant.The warrants will have an exercise price of $1.19 per share and will expire five years from the initial exercise date.The offering is expected to close on or about April 4.The company will use the net proceeds from the offering for the continued clinical development of product candidates, as working capital, and for other general corporate purposes.On Stocktwits, retail investor sentiment about Aptevo jumped from ‘extremely bearish’ to ‘extremely bullish’ territory (97/100), hitting a one-year high. At the same time, message volume touched ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:652/153;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_03_at_11_35_45_AM_png_96a7494386.webp" alt="https://stocktwits.com/news-articles/markets/equity/trump-liberation-day-impact-steel-stocks-tumble-with-broader-market/chf7RL4RbeK" width="652" height="153"><figcaption>APVO's Sentiment Meter and Message Volume as of 11:35 a.m. ET on April 3, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the registered direct offering may be a “bailout” to institutions who were short.&nbsp;<stembedurl>https://stocktwits.com/leon_dedrick/message/610264441</stembedurl>Another user, however, expressed optimism about the share price rising to $3.<stembedurl>https://stocktwits.com/Bulltacos/message/610259261</stembedurl><a href="https://stocktwits.com/symbol/APVO">APVO shares</a> have lost over 55% this year and nearly all its value over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/trump-liberation-day-impact-steel-stocks-tumble-with-broader-market/chf7RL4RbeK">Trump’s Liberation Day Impact – Steel Stocks Tumble With Broader Market, UBS Flags Tariffs As 'Incremental Negative' For These Companies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail  Sentiment Touches Year-High

The company said that net proceeds from the offering will be used for the continued clinical development of product candidates, as working capital, and for other general corporate purposes.

Aptevo Therapeutics Inc. shares surged nearly 50% early Thursday on promising leukemia trial results, before paring gains in volatile trading.&nbsp;The stock drew significant heavy interest on Stocktwits, reaching the top 15 trending symbols list, where sentiment turned ‘extremely bullish’ amid a sharp rise in message volume.<figure class="image"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/APVO_sentiment_and_message_volume_on_Dec_12_f6c2ca53dd.png" alt="APVO sentiment and message volume on Dec 12.png" width="1314" height="320"><figcaption>APVO sentiment and message volume on Dec 12 as of 11:45 am ET | source: Stocktwits</figcaption></figure>The company announced that all patients with acute myeloid leukemia (AML) treated with its lead candidate, mipletamig, achieved remission within 30 days in a Phase 1b trial.&nbsp;This includes two patients who experienced complete remission with 100% cancer cell elimination.&nbsp;The trial is exploring mipletamig as frontline therapy in combination with venetoclax and azacitidine, the current standard of care for AML.Retail traders speculated heavily on the stock’s movements, attributing volatility to its small public float of around 500,000 shares.&nbsp;Optimistic users expressed confidence in the company’s long-term potential, with one noting that they had bought 1,000 shares of Aptevo.Aptevo’s oncology pipeline targets aggressive forms of cancer. Other highlights include:• ALG.APV-527: Currently in Phase 1 for 5T4-expressing solid tumors like breast, colon, and non-small cell lung cancers. Preliminary data presented at leading oncology conferences has been positive.• Other preclinical candidates, including APVO711 (immune checkpoint blockade and activator) and APVO603 (dual co-stimulatory solid tumor targeting), are designed for precision cancer treatments.Aptevo stock remains down over 96% year-to-date, reflecting other ongoing challenges. Its current market cap is just over $5 million.Still, retail investors remain cautiously optimistic for now as the company builds on promising clinical data while addressing broader market pressures.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Aptevo Therapeutics Stock Draws Retail Attention After Leukemia Trial Data: Retail Extremely Bullish

The company announced that all patients with acute myeloid leukemia treated with its lead candidate, mipletamig, achieved remission within 30 days in a Phase 1b trial.

Why Aptevo Therapeutics Stock Is Cratering

Aptevo announced the pricing of a public offering of 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and warrants to purchase up to an aggregate of 6,800,000 shares of its...

Aptevo Therapeutics (NASDAQ:APVO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO - Free Report) in a research report report published on Tuesday morning. The brokerage issued a hold rating on the...

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

SEATTLE, WA / ACCESSWIRE / March 18, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its...

Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO  Free Report) in a research note released on Sunday. The firm issued a hold rating on the biotechnology...

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers...

Why Is Immuno-Oncology Focused Aptevo Therapeutics Stock Trading Higher On Thursday?

Interim results from the Phase 1 trial of ALG.APV-527 by Alligator Bioscience and Aptevo Therapeutics. Positive signs of clinical activity in breast cancer patients, with well-tolerated treatment and...

Aptevo Therapeutics trading resumes

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

Aptevo Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$1.52
Prev Close	$1.53
Open	$1.54
Dividend Yield	0.00%
50-Day Moving Average	$1.65
Beta	0.96
Avg. Volume	12.66M
PE Ratio	0.00

52-Week High	$298.00
52-Week Low	$1.32
Market Capitalization	$20.99M
EPS (Annual)	-$1,747.68
Price to Book	0.75
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

APVO
Aptevo Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest APVO News

APVOAptevo Therapeutics Inc